Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease

Chauhan, 2006, Oxidative stress in Alzheimer's disease, Pathophysiology, 13, 195, 10.1016/j.pathophys.2006.05.004

Mattson, 1997, Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives, Physiol Rev, 77, 1081, 10.1152/physrev.1997.77.4.1081

Bonifati, 2007, Role of complement in neurodegeneration and neuroinflammation, Mol Immunol, 44, 999, 10.1016/j.molimm.2006.03.007

Akiyama, 2000, Inflammation and Alzheimer's disease, Neurobiol Aging, 21, 383, 10.1016/S0197-4580(00)00124-X

Tarkowski, 2003, Cerebral pattern of pro- and anti-inflammatory cytokines in dementias, Brain Res Bull, 61, 255, 10.1016/S0361-9230(03)00088-1

Wada-Isoe, 2004, Elevated interleukin-6 levels in cerebrospinal fluid of vascular dementia patients, Acta Neurol Scand, 110, 124, 10.1111/j.1600-0404.2004.00286.x

Ke, 2006, Peripheral inflammatory mechanisms modulate microglial activation in response to mild impairment of oxidative metabolism, Neurochem Int, 49, 548, 10.1016/j.neuint.2006.04.011

Zipp, 2006, The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases, Trends Neurosci, 29, 518, 10.1016/j.tins.2006.07.006

Winblad, 2004, Mild cognitive impairment—beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment, J Intern Med, 256, 240, 10.1111/j.1365-2796.2004.01380.x

Morris, 2001, Mild cognitive impairment represents early-stage Alzheimer disease, Arch Neurol, 58, 397, 10.1001/archneur.58.3.397

Levey, 2006, Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease, Clin Ther, 28, 991, 10.1016/j.clinthera.2006.07.006

Nybo, 2002, Interleukin-6 release from the human brain during prolonged exercise, J Physiol, 542, 991, 10.1113/jphysiol.2002.022285

Pollmacher, 2002, Low levels of circulating inflammatory cytokines—do they affect human brain functions?, Brain Behav Immun, 16, 525, 10.1016/S0889-1591(02)00004-1

De Simoni, 1990, Intracerebroventricular injection of interleukin 1 induces high circulating levels of interleukin 6, J Exp Med, 171, 1773, 10.1084/jem.171.5.1773

Romero, 1996, Interleukin-6 (IL-6) is secreted from the brain after intracerebroventricular injection of IL-1 beta in rats, Am J Physiol, 270, R518

Petersen, 2001, Current concepts in mild cognitive impairment, Arch Neurol, 58, 1985, 10.1001/archneur.58.12.1985

McKhann, 1984, Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology, 34, 939, 10.1212/WNL.34.7.939

Tinetti, 1986, Performance-oriented assessment of mobility problems in elderly patients, J Am Geriatr Soc, 34, 119, 10.1111/j.1532-5415.1986.tb05480.x

Ankri, 2005, Beyond the global score of the Zarit Burden Interview: useful dimensions for clinicians, Int J Geriatr Psychiatry, 20, 254, 10.1002/gps.1275

Cockrell, 1988, Mini-mental state examination (MMSE), Psychopharmacol Bull, 24, 689

Schmand, 2000, Early detection of Alzheimer's disease using the Cambridge cognitive examination (CAMCOG), Psychol Med, 30, 619, 10.1017/S0033291799002068

Makatura, 1999, Standardized memory tests and the appraisal of everyday memory, Brain Inj, 13, 355, 10.1080/026990599121548

Cummings, 1994, The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia, Neurology, 44, 2308, 10.1212/WNL.44.12.2308

Torres, 2004, Observational scale and geriatric depression scale of Yesavage to identify depressive symptoms in older patients, Arch Gerontol Geriatr, 437, 10.1016/j.archger.2004.04.056

Ready, 2002, The Cornell-Brown scale for quality of life in dementia, Alzheimer Dis Assoc Disord, 16, 109, 10.1097/00002093-200204000-00008

Baskin, 2001, Platelet APP isoform ratios in asymptomatic young adults expressing an AD-related presenilin-1 mutation, J Neurol Sci, 183, 85, 10.1016/S0022-510X(00)00483-4

Bauer, 1991, Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices, FEBS Lett, 285, 111, 10.1016/0014-5793(91)80737-N

Strauss, 1992, Detection of interleukin-6 and alpha 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients, Lab Invest, 66, 223

Huell, 1995, Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients, Acta Neuropathol (Berl), 89, 544, 10.1007/BF00571510

Angelis, 1998, Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease, Neurosci Lett, 244, 106, 10.1016/S0304-3940(98)00136-0

van Duijn, 1990, Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease, Neurosci Lett, 108, 350, 10.1016/0304-3940(90)90666-W

Licastro, 2000, Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?, J Neuroimmunol, 103, 97, 10.1016/S0165-5728(99)00226-X

Singh, 1997, Circulating cytokines in Alzheimer's disease, J Psychiatr Res, 31, 657, 10.1016/S0022-3956(97)00023-X

Morley, 2004, Cytokine-related aging process, J Gerontol A Biol Sci Med Sci, 59, M924, 10.1093/gerona/59.9.M924

Simen, 2006, TNFalpha signaling in depression and anxiety: behavioral consequences of individual receptor targeting, Biol Psychiatry, 59, 775, 10.1016/j.biopsych.2005.10.013

Paganelli, 2002, Proinflammatory cytokines in sera of elderly patients with dementia: levels in vascular injury are higher than those of mild–moderate Alzheimer's disease patients, Exp Gerontol, 37, 257, 10.1016/S0531-5565(01)00191-7

Tarkowski, 2003, Intrathecal inflammation precedes development of Alzheimer's disease, J Neurol Neurosurg Psychiatry, 74, 1200, 10.1136/jnnp.74.9.1200

Magaki, 2007, Increased production of inflammatory cytokines in mild cognitive impairment, Exp Gerontol, 42, 233, 10.1016/j.exger.2006.09.015

Hauser, 2002, A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C, Mol Psychiatry, 7, 942, 10.1038/sj.mp.4001119

Pariante, 1999, Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders, Lancet, 354, 131, 10.1016/S0140-6736(98)04793-X

Raison, 2005, Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction, J Clin Psychiatry, 66, 41, 10.4088/JCP.v66n0106

Musselman, 2001, Paroxetine for the prevention of depression induced by high-dose interferon alfa, N Engl J Med, 344, 961, 10.1056/NEJM200103293441303

Schonknecht, 2007, Increased tau protein differentiates mild cognitive impairment from geriatric depression and predicts conversion to dementia, Neurosci Lett, 416, 39, 10.1016/j.neulet.2007.01.070

Capuron, 2003, Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy, Am J Psychiatry, 160, 1342, 10.1176/appi.ajp.160.7.1342

Cassidy, 2002, Acute effects of low-dose interferon-alpha on serum cortisol and plasma interleukin-6, J Psychopharmacol, 16, 230, 10.1177/026988110201600307

Shimizu, 1995, Increase in serum interleukin-6, plasma ACTH and serum cortisol levels after systemic interferon-alpha administration, Endocr J, 42, 551, 10.1507/endocrj.42.551

Sissolak, 1992, Effects of interferon-alpha (IFN) on the expression of interleukin 1-beta (IL-1), interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor-alpha (TNF) in acute myeloid leukemia (AML) blasts, Leukemia, 6, 1155

Taylor, 1998, The effects of interferon-alpha on the production and action of other cytokines, Semin Oncol, 25, 23

Dieperink, 2003, A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C, Psychosomatics, 44, 104, 10.1176/appi.psy.44.2.104

Russo, 2005, Irritability rather than depression during interferon treatment is linked to increased tryptophan catabolism, Psychosom Med, 67, 773, 10.1097/01.psy.0000171193.28044.d8

Valentine, 2005, Neurobehavioral effects of interferon therapy, Curr Psychiatry Rep, 7, 391, 10.1007/s11920-005-0042-3

Bonaccorso, 2002, Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system, J Clin Psychopharmacol, 22, 86, 10.1097/00004714-200202000-00014

Bonaccorso, 2001, Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms, Psychiatry Res, 105, 45, 10.1016/S0165-1781(01)00315-8

Capuron, 2002, Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy, Mol Psychiatry, 7, 468, 10.1038/sj.mp.4000995

Miyaoka, 1999, Depression from interferon therapy in patients with hepatitis C, Am J Psychiatry, 156, 1120, 10.1176/ajp.156.7.1120

Raison, 2006, Cytokines sing the blues: inflammation and the pathogenesis of depression, Trends Immunol, 27, 24, 10.1016/j.it.2005.11.006

Weber, 2002, Flow cytometry analysis of platelet cyclooxygenase-2 expression: induction of platelet cyclooxygenase-2 in patients undergoing coronary artery bypass grafting, Br J Haematol, 117, 424, 10.1046/j.1365-2141.2002.03423.x

Weber, 1999, Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance, Lancet, 353, 900, 10.1016/S0140-6736(99)00498-5

Struber, 1999, Human cytokine responses to coronary artery bypass grafting with and without cardiopulmonary bypass, Ann Thorac Surg, 68, 1330, 10.1016/S0003-4975(99)00729-8

Vane, 1998, Cyclooxygenases 1 and 2, Annu Rev Pharmacol Toxicol, 38, 97, 10.1146/annurev.pharmtox.38.1.97

Censarek, 2004, Cyclooxygenase COX-2a, a novel COX-2 mRNA variant, in platelets from patients after coronary artery bypass grafting, Thromb Haemost, 92, 925, 10.1160/TH04-05-0302

Barone, 2006, Role of inflammation and cellular stress in brain injury and central nervous system diseases, Clin Neurosci Res, 6, 329, 10.1016/j.cnr.2006.09.010

Christen, 2000, Oxidative stress and Alzheimer disease, Am J Clin Nutr, 71, 621S, 10.1093/ajcn/71.2.621s

Colton, 1987, Production of superoxide anions by a CNS macrophage, the microglia, FEBS Lett, 223, 284, 10.1016/0014-5793(87)80305-8

Klegeris, 1994, Rat brain microglia and peritoneal macrophages show similar responses to respiratory burst stimulants, J Neuroimmunol, 53, 83, 10.1016/0165-5728(94)90067-1

Bermejo, 2008, Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from mild cognitive impairment, Free Radic Res, 42, 162, 10.1080/10715760701861373